Kangmei Pharmaceutical Hits Day Low of CNY 1.35 Amid Price Pressure

Kangmei Pharmaceutical Co., Ltd. experienced a significant decline in its stock performance on July 17, 2026, with a drop of 6.9%. The stock reached an intraday low of CNY 1.35, reflecting ongoing challenges within the company. Over the past year, Kangmei has faced substantial difficulties, with a staggering 35.71% decrease in stock value, contrasting sharply with the China Shanghai Composite's 7.03% gain during the same period. The company's financial metrics indicate a concerning trend, with net profit plummeting by 256.66% to CNY -3.8 million in the latest quarter. Additionally, the return on equity stands at a low -0.17%, and the price-to-book ratio is notably high at 2.71, suggesting an expensive valuation relative to its book value. Despite a brief uptick of 5.47% over the past week, Kangmei's long-term performance remains troubling, with a staggering 92% decline over the last decade. These figures highlight the ongoing challenges faced by Kangmei Pharmaceutical in a competitive market.